August 19, 2022 02:00 ET | Source: Karolinska Development AB (publ) Karolinska Development AB (publ)
STOCKHOLM – 19 August 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2022. The full report is available on the Company's website.
“Our portfolio companies’ dedicated work, clear progress, and ability to identify strategically advantageous partnerships and acquisition opportunities are impressive, and bode well for ongoing value creation”, says Viktor Drvota, CEO, Karolinska Development.
Significant events during the second quarter
The Interim Report for Karolinska Development AB for the period January-June 2022 is available as a PDF at www.karolinskadevelopment.com.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Per Aniansson, CFO, Karolinska Development AB Phone: +46 70 866 04 29, e-mail: per.aniansson@karolinskadevelopment.com
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com